NASDAQ: ZYMEZymeworks Inc Stock Ownership - Who owns Zymeworks?
Insider buying vs selling
Have Zymeworks Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jeffrey T. L. Smith | EVP Chief Medical Officer | 2026-01-12 | 9,310 | $22.67 | $211.09kSell |
| Mark Hollywood | EVP Chief Operating Officer | 2026-01-12 | 6,120 | $22.67 | $138.76kSell |
| Kenneth Galbraith | Chair CEO | 2026-01-12 | 30,424 | $22.67 | $689.83kSell |
| Paul Andrew Moore | Chief Scientific Officer | 2026-01-12 | 9,560 | $22.67 | $216.76kSell |
| Leone D. Patterson | EVP Chief Bus Fin Officer | 2026-01-06 | 459 | $10.55 | $4.84kBuy |
| Kenneth Galbraith | Chair CEO | 2026-01-05 | 22,657 | $25.10 | $568.62kSell |
| Jeffrey T. L. Smith | EVP Chief Medical Officer | 2026-01-05 | 10,538 | $25.10 | $264.47kSell |
| Paul Andrew Moore | Chief Scientific Officer | 2026-01-05 | 10,821 | $25.10 | $271.57kSell |
| Paul Andrew Moore | Chief Scientific Officer | 2026-01-05 | 9,289 | $25.10 | $233.13kSell |
| Kenneth Galbraith | Chair CEO | 2026-01-05 | 31,686 | $25.10 | $795.22kSell |
ZYME insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when ZYME insiders and whales buy or sell their stock.
ZYME Shareholders
What type of owners hold Zymeworks Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Ecor1 Capital LLC | 54.02% | 40,426,434 | $918.49M | Insider |
| Ecor1 Capital LLC | 30.69% | 22,970,388 | $521.89M | Institution |
| Oleg Nodelman | 21.01% | 15,720,161 | $357.16M | Insider |
| Redmile Group LLC | 8.08% | 6,045,437 | $137.35M | Insider |
| Rubric Capital Management LP | 6.29% | 4,710,551 | $107.02M | Institution |
| Blackrock Inc | 5.33% | 3,989,533 | $90.64M | Institution |
| Morgan Stanley | 5.32% | 3,984,585 | $90.53M | Institution |
| Bvf Inc | 5.26% | 3,938,641 | $89.49M | Institution |
| Redmile Group LLC | 4.95% | 3,705,750 | $84.19M | Institution |
| Vanguard Group Inc | 2.88% | 2,154,434 | $48.95M | Institution |
ZYME vs Biotech Stocks
Zymeworks Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.